Micronomicin sulfate (Gentamicin C2b sulfate) is an aminoglycoside antibiotic isolated from Micromonospora . Micronomicin sulfate is a broad-spectrum antibiotic close to the gentamicin-type antibiotics , exhibits a high activity against Pseudomonas , Proteus , Klebsiella pneumoniae , Serratia , etc ( MIC =0.001-8.3 μg/ml) In Vitro Micronomicin has a potent antibacterial activity, it is active against Staphylococcus aureus FDA 209 P, Staphylococcus aureus with the minimal inhibitory values of 0.01 μg/ml. It is also against Escherichia coli St.M. 589, Baker 2, F 14-BK, and R5/W677 with the minimal inhibitory values of 0.75 μg/ml, 0.3 μg/ml, 0.03 μg/ml and 0.03 μg/ml. And it is active against Pseudomonas aeruginosa strains and lebsiella pneumoniae strains (MICs = 0.03-17.5 μg/ml). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Micronomicin sulfate is highly active against various bacterial infections in mice, and has an intravenous acute LD 50 in mice of 93 mg/kg . Micronomicin sulfate (intravenous injection; 4-100 mg/kg; 30 days) is injected for subacute toxicity study. The wistar rats dies at the dose level of 100 mg/kg (10 out of 30 animals): renal disorders and ataxia. The renal histological disorders occurrs mainly at the dose levels of 25 mg/kg and over. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Wistar ratsDosage: 4, 10, 25, 63 mg/kg and 100 mg/kg Administration: Intravenous injection; 30 days Result: Led to death of rat at 100 mg/kg. Form:Solid IC50& Target:Aminoglycoside